Artiva Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Artiva Biotherapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-27.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 63% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -2%In 3 years sales changed by -100% while total assets changed by -2%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-25.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 60% of Healthcare companies in United States.
Cash Cushion Ratio
+32%Cash, after subtracting all debt, equals 32% of its market value (net cash).
Higher than 69% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Artiva Biotherapeutics, Inc. made a loss over the last year. Artiva Biotherapeutics, Inc. owes $0.06 for every $1 it owns. Artiva Biotherapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossArtiva Biotherapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.87The share price is 0.87 times Artiva Biotherapeutics, Inc.'s book value per share, lower than 81% of Healthcare companies in United States.
Market cap
$303 MThe total market value of all of Artiva Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 52% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$348 MWhat Artiva Biotherapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.11Net worth divided by the number of shares. The share price of $6.20 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-36.6%Artiva Biotherapeutics, Inc. lost 36.6% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
Owes vs Owns
0.06×Artiva Biotherapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Dividend yield
NoneArtiva Biotherapeutics, Inc. does not currently pay a dividend.
Profit growth
LossArtiva Biotherapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashArtiva Biotherapeutics, Inc. held $97 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Artiva Biotherapeutics, Inc.: $303 M ÷ $348 M (30 Jun 2026) = 0.9.
What is Artiva Biotherapeutics, Inc.'s return on equity?
Artiva Biotherapeutics, Inc. lost 36.6% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
How much does Artiva Biotherapeutics, Inc. owe compared with what it owns?
Artiva Biotherapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Does Artiva Biotherapeutics, Inc. pay a dividend?
No. Artiva Biotherapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.